# US 2026/0027149 A1 · Nitric oxide gas-infused liquids and related methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027149 A1
- Document ID: US20260027149A1
- Status: Published application
- Kind: A1
- Application number: 19/283,219
- Filed: 2025-07-28
- Published: 2026-01-29
- Earliest claimed: 2024-07-26
- Assignees: ThermoLife International, LLC
- Applicants: ThermoLife International, LLC
- Inventors: Ronald KRAMER; Alexandros NIKOLAIDIS
- Web page: https://patentgrep.com/patent/US20260027149A1

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C01B 21/24: Nitric oxide (NO) {(C01B21/203 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}

## Abstract

A novel method of producing an NO+H2 solution is disclosed as well as liquid compositions comprising stable and high concentrations of NO and H2.

## Claims

### Claim 1

A nitric oxide stabilized liquid composition comprising:
a liquid;
nitric oxide gas (NO); and
hydrogen gas (H2);
wherein the NO and the H2 are diffused in the liquid to produce the nitric oxide stabilized liquid.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the NO and the H2 are diffused in the liquid comprises the NO and the H2 being dissolved in the liquid.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the liquid comprises water.

### Claim 4 (depends on 1)

The composition of claim 1, wherein concentration of the NO and the H2 are respectively at least 1 ppm and at least 100 ppb.

### Claim 5 (depends on 1)

The composition of claim 1 further comprising a pharmaceutically acceptable additive.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the pharmaceutically acceptable additive is selected from: a carrier, an excipient, a binder, a colorant, a flavoring agent, a preservative, a buffer, a diluent, and combinations thereof.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the pharmaceutically acceptable additive is a food additive.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the composition is in an administration container.

### Claim 9

A nitric oxide and hydrogen (NOH2) administration container comprising:
a) a liquid;
b) nitric oxide gas (NO); and
c) hydrogen gas (H2),
d) wherein the NO and the H2 are diffused in the liquid.

### Claim 10 (depends on 9)

The NOH2 administration container of claim 9, wherein the NO and the H2 are dissolved in the liquid.

### Claim 11 (depends on 9)

The NOH2 administration container of claim 9, wherein the liquid comprises water.

### Claim 12 (depends on 9)

The NOH2 administration container of claim 9, wherein concentration of the NO and the H2 are respectively at least 1 ppm and at least 100 ppb.

### Claim 13 (depends on 9)

The NOH2 administration container of claim 9, further comprising a pharmaceutically acceptable additive.

### Claim 14 (depends on 13)

The NOH2 administration container of claim 13, wherein the pharmaceutically acceptable additive is selected from the group consisting of: a carrier, an excipient, a binder, a colorant, a flavoring agent, a preservative, a buffer, a diluent, and combinations thereof.

### Claim 15 (depends on 13)

The NOH2 administration container of claim 13, wherein the pharmaceutically acceptable additive is a botanical additive derived from a plant including a fruit of a plant.

### Claim 16 (depends on 13)

The NOH2 administration container of claim 13, wherein the liquid comprises a botanical liquid.

### Claim 17 (depends on 16)

The NOH2 administration container of claim 16, wherein the botanical liquid is a fruit juice.

### Claim 18 (depends on 13)

The NOH2 administration container of claim 13, wherein the pharmaceutically acceptable additive is a food additive.

### Claim 19 (depends on 18)

The NOH2 administration container of claim 18, wherein the food additive is a liquid.

### Claim 20 (depends on 19)

The NOH2 administration container of claim 19, wherein the liquid is milk.

### Claim 21 (depends on 9)

The NOH2 administration container of claim 9, wherein the liquid comprises blood.

### Claim 22 (depends on 9)

The NOH2 administration container of claim 9, wherein the administration container is a beverage container comprising a container wall with a consumption opening and an opening closure that seals the nitric oxide stabilized liquid in the container.

### Claim 23 (depends on 22)

The NOH2 administration container of claim 22, wherein the beverage container is pressurized with NO.

### Claim 24 (depends on 22)

The NOH2 administration container of claim 22, wherein the beverage container is a metal can.

### Claim 25 (depends on 24)

The NOH2 administration container of claim 24, wherein the beverage container is an aluminum can.

### Claim 26 (depends on 22)

The NOH2 administration container of claim 22, wherein the beverage container is pressurized to 2 atmospheres or more.

### Claim 27 (depends on 26)

The NOH2 administration container of claim 26, wherein the beverage container is pressurized to 4 atmospheres or more.

### Claim 28 (depends on 27)

The NOH2 administration container of claim 27, wherein the beverage container is pressurized to 6 atmospheres or more.

### Claim 29 (depends on 9)

The NOH2 administration container of claim 9, wherein the administration container is an intravenous (IV) container.

### Claim 30 (depends on 9)

The NOH2 administration container of claim 9, wherein the administration container is a vape container configured for insertion into a vape device for inhalation of the nitric oxide stabilized liquid as a vapor therefrom.

### Claim 31 (depends on 9)

The NOH2 administration container of claim 9, wherein the administration container is capsule for oral consumption.

### Claim 32

A method of producing a nitric oxide stabilized liquid having stabilized nitric oxide gas (NO) dissolved therein comprising:
a) providing a nitric oxide liquid with NO dissolved therein with a concentration of least 1 ppm;
b) providing hydrogen gas (H2); and
c) dissolving the H2 in the liquid at a concentration of at least 100 ppb to produce the nitric oxide stabilized liquid.

### Claim 33 (depends on 32)

The method of claim 32, wherein the nitric oxide stabilized liquid comprises oxygen.

### Claim 34 (depends on 32)

The method of claim 32, wherein the NO concentration in the liquid is stable having less than a 25% drop in NO concentration in 24 hours after the addition of H2.

### Claim 35 (depends on 34)

The method of claim 34, wherein providing a nitric oxide liquid with NO dissolved therein with a concentration of least 1 ppm comprises:
a) providing NO;
b) providing a liquid; and
c) dissolving the NO in the liquid to produce the nitric oxide liquid with a concentration of least 1 ppm.

### Claim 36

A method of producing a nitric oxide stabilized liquid comprising:
a) providing a liquid;
b) providing nitric oxide gas (NO);
c) providing hydrogen gas (H2); and
d) simultaneously dissolving in the liquid the NO and the H2 to produce the nitric oxide stabilized liquid.

### Claim 37 (depends on 36)

The method of claim 36, wherein the NO is at a concentration of least 1 ppm and the H2 is at a concentration of at least 100 ppb in the nitric oxide stabilized liquid.

### Claim 38 (depends on 36)

The method of claim 36, wherein the nitric oxide stabilized liquid comprises oxygen.

### Claim 39 (depends on 36)

The method of claim 36, wherein the NO concentration in the liquid is stable having less than a 25% drop in NO concentration in 24 hours after the simultaneous addition of NO and H2.

### Claim 40

A method of increasing nitric oxide levels in blood of a subject comprising:
a) providing a nitric oxide stabilized liquid comprising nitric oxide gas (NO) at a concentration of at least 1 ppm and hydrogen gas (H2) at a concentration of least 100 ppb in the nitric oxide stabilized liquid;
b) administering the nitric oxide stabilized liquid to the subject.

### Claim 41 (depends on 40)

The method of claim 40, wherein administering the nitric oxide stabilized liquid includes drinking the nitric oxide stabilized liquid.

### Claim 42 (depends on 41)

The method of claim 41, wherein the nitric oxide stabilized liquid is administered in a dose of 1-10,000 ml.

### Claim 43 (depends on 42)

The method of claim 42, wherein the nitric oxide stabilized liquid is administered in a dose of 10-5,000 ml.

### Claim 44 (depends on 43)

The method of claim 43, wherein the nitric oxide stabilized liquid is administered in a dose of 100-1,000 ml.

### Claim 45 (depends on 40)

The method of claim 40, wherein administering the nitric oxide stabilized liquid includes intravenous introduction of the nitric oxide stabilized liquid.

### Claim 46 (depends on 45)

The method of claim 45, wherein the nitric oxide stabilized liquid is administered at an infusion rate of 0.1-10 ml/min.

### Claim 47 (depends on 40)

The method of claim 40, wherein the method is for treating methemoglobinemia.

### Claim 48 (depends on 40)

The method of claim 40, wherein the method is for treating any one of: hypertension; atherosclerosis; varicose veins; low oxygen saturation/hypoxia; gastrointestinal ulcers; viral, fungal, bacterial, protozoa, or parasitic infections; migraine; or anemia.

### Claim 49 (depends on 40)

The method of claim 40, wherein the method is for reducing inflammation.

### Claim 50 (depends on 40)

The method of claim 40, wherein the method is for reducing F2-isoprostane.
